With over 7 million people over 65 dealing with the degenerative disease — and the number expected to almost double by 2050 — Alzheimer’s is the most common form of dementia. But two new ...

The drug, tolebrutinib, delayed disability progression by 31% in people with a type of MS called non-relapsing secondary progressive multiple sclerosis, researchers reported in the New England Journal ...

Drug maker Novo Nordisk says semaglutide, the active ingredient for the weight loss jab Wegovy, does not slow Alzheimer's - despite initial hopes that it might help against dementia. Researchers began ...

Long before memory problems appear, your brain may already be losing neurons. That is the unsettling message from new work by ...

Deciding which jab to nab? When it comes to shedding pounds and cinching inches, a new study puts one weight loss drug ahead of another. Published in the New England Journal of Medicine, the study ...

A new drug may slow progression of — and even reverse — symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...

Glucagon-like peptide 1 (GLP-1) receptor agonists are transforming the treatment landscape for type 2 diabetes ( T2D) and obesity, in addition to their cardiovascular benefits. These drugs also show ...